A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First‐line Therapy (KCSG ST10‐01)

LESSONS LEARNED. Irinotecan could not be proven noninferior to paclitaxel as a second‐line treatment for patients with metastatic or recurrent gastric cancer. The failure to demonstrate noninferiority may have been a result of insufficient patient enrollment. Both agents were tolerable but showed di...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Keun‐Wook, Maeng, Chi Hoon, Kim, Tae‐You, Zang, Dae Young, Kim, Yeul Hong, Hwang, In Gyu, Oh, Sang Cheul, Chung, Joo Seop, Song, Hong Suk, Kim, Jin Won, Jeong, Su Jin, Cho, Jae Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324622/
https://www.ncbi.nlm.nih.gov/pubmed/30126861
http://dx.doi.org/10.1634/theoncologist.2018-0142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324622/
https://www.ncbi.nlm.nih.gov/pubmed/30126861
http://dx.doi.org/10.1634/theoncologist.2018-0142

Ejemplares similares